Comparative Pharmacology
Head-to-head clinical analysis: CHLOROTHIAZIDE SODIUM versus HYDROFLUMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROTHIAZIDE SODIUM versus HYDROFLUMETHIAZIDE.
CHLOROTHIAZIDE SODIUM vs HYDROFLUMETHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in distal convoluted tubule of nephron, reducing sodium reabsorption and promoting diuresis.
Hydroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and promoting diuresis. It also causes vasodilation by reducing peripheral vascular resistance.
500 mg to 1 g orally or intravenously once or twice daily.
Oral: 25-50 mg once daily; may increase to 100 mg/day in divided doses if needed.
None Documented
None Documented
Terminal elimination half-life is 45–120 minutes in patients with normal renal function; prolonged in renal impairment (up to 24 hours in anuria).
Clinical Note
moderateHydroflumethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digoxin."
Clinical Note
moderateHydroflumethiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digitoxin."
Clinical Note
moderateHydroflumethiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Deslanoside."
Clinical Note
moderateTerminal elimination half-life of 6-9 hours in patients with normal renal function; clinically, this supports once-daily dosing in hypertension but may require twice-daily dosing in some patients with impaired renal function
Primarily renal excretion via tubular secretion; approximately 95% of absorbed dose excreted unchanged in urine within 24 hours, with less than 5% eliminated via bile/feces.
Primarily renal (approximately 85% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%)
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic
Hydroflumethiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Acetyldigitoxin."